ArticlePloS one2015
BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present.Journal of ovarian research · 2022Pooled it
- Reproductive Challenges in Mutated BRCA Gene Carriers: A Narrative Review.Current issues in molecular biology · 2026Review
- Directional and disruptive selection in populations structured by class and continuous ontogeny under incomplete plasticity.PLoS computational biology · 2026Article
- Screening of the founder pathogenic variants BRCA1 and BRCA2 in Russian metropolitan women.BMC women's health · 2025Article
- Susceptibility of Brca1Cancer science · 2025Article
- Reduced reproductive potential in young healthy women with hereditary breast and/or ovarian cancer syndrome.Communications medicine · 2025Article
- Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells.Cancer cell international · 2024Article
- Fertility Preservation in BRCA1/2 Germline Mutation Carriers: An Overview.Life (Basel, Switzerland) · 2024Review
- Reproductive outcomes in women with BRCA 1/2 germline mutations: A retrospective observational study and literature review.Open medicine (Warsaw, Poland) · 2024Article
- More evidence for widespread antagonistic pleiotropy in polymorphic disease alleles.Frontiers in genetics · 2024Review
- Oncogenic BRCA1,2 Mutations in the Human Lineage-A By-Product of Sexual Selection?Biomedicines · 2023Review
- The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status.Reproductive sciences (Thousand Oaks, Calif.) · 2023Article
- Surgical management of a congenital genital tract abnormality in a patient with Lynch syndrome.BMJ case reports · 2022Article
- Modalities of aging in organisms with different strategies of resource allocation.Ageing research reviews · 2022Review
- Review
- BRCA1/2 pathogenetic variant carriers and reproductive decisions: Gender differences and factors associated with the choice of preimplantation genetic diagnosis (PGD) and prenatal diagnosis (PND).Journal of assisted reproduction and genetics · 2022Review
- Pregnancy after breast cancer in BRCA1/2 mutation carriers.Hereditary cancer in clinical practice · 2022Review
- BRCA1: An Endocrine and Metabolic Regulator.Frontiers in endocrinology · 2022Review
- Association between hereditary predisposition to common cancers and congenital multimalformations.Congenital anomalies · 2020Article
- BRACAVENIR: an observational study of expectations and coping in young women with high hereditary risk of breast and ovarian cancer.Hereditary cancer in clinical practice · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDeleterious mutations in the BRCA genes are responsible for a small, but significant, proportion of breast and ovarian cancers (5 - 10 %). Proof of de novo mutations in hereditary breast/ovarian cancer (HBOC) families is rare, in contrast to founder mutations, thousands of years old, that may be carried by as much as 1 % of a population. Thus, if mutations favoring cancer survive selection pressure through time, they must provide advantages that compensate for the loss of life expectancy.
methodThis hypothesis was tested within 2,150 HBOC families encompassing 96,325 individuals. Parameters included counts of breast/ovarian cancer, age at diagnosis, male breast cancer and other cancer locations. As expected, well-known clinical parameters discriminated between BRCA-mutated families and others: young age at breast cancer, ovarian cancer, pancreatic cancer and male breast cancer. The major fertility differences concerned men in BRCA-mutated families: they had lower first and mean age at paternity, and fewer remained childless. For women in BRCA families, the miscarriage rate was lower. In a logistic regression including clinical factors, the different miscarriage rate and men's mean age at paternity remained significant.
resultsFertility advantages were confirmed in a subgroup of 746 BRCA mutation carriers and 483 non-carriers from BRCA mutated families. In particular, female carriers were less often nulliparous (9.1 % of carriers versus 16.0 %, p = 0.003) and had more children (1.8 ± 1.4 SD versus 1.5 ± 1.3, p = 0.002) as well as male carriers (1.7 ± 1.3 versus 1.4 ± 1.3, p = 0.024).
conclusionAlthough BRCA mutations shorten the reproductive period due to cancer mortality, they compensate by improving fertility both in male and female carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.